Photopheresis (also known as extracorporeal photochemotherapy, ECP) is a blood-filtering treatment that works with your body’s own immune system to treat disease. This immunotherapy was developed by a Yale Medicine dermatologist to treat cutaneous T-cell lymphomas, a rare group of cancers that usually affects the skin but sometimes can be found in the blood, lymph nodes and other internal organs.
Over time, the treatment has been used for other health issues like graft-versus-host disease (GVHD, in which donated bone marrow or blood stem cells attack the recipient’s body) and organ rejection. Today, Photopheresis is being investigated as a potential treatment for other autoimmune diseases.
What’s unique about Photopheresis is how it can be tailored to particular needs. Sometimes it is used as a kick-start, to strengthen an immune response, while in other situations it provides what amounts to a “reset,” halting a problematic immune response.
“People are surprised that you can have one therapy capable of turning on the immune system when you need a stronger reaction, like with cancer. Or turning it off, when the immune system is actually causing the problem, like with a reactive organ transplantation rejection,” says chief of Yale Medicine Dermatology Richard Edelson, MD, who developed the treatment in 1987.
At Yale Medicine Dermatology’s ECP (Photopheresis) Immunotherapy Program, our dermatology team treats patients with cutaneous T-cell lymphoma, GVHD and organ transplant rejection. Our physician-scientists are actively studying how Photopheresis may be used to treat a host of other immunologic disorders.